Emergent drugs (I): smart drugs
Keywords:
Smart-drugs. Piperacinas. Catinonas. Mefedrona. Spice.Abstract
In recent years, a series of new drugs, known as smart drugs or legal highs, have gaining in popularity. They are easily obtainable through online shops. This is happening amongst younger segments of the population and is associated with recreational consumption, at weekends. In general, they are synthetic derivatives of natural products. There has been hardly any clinical research into them and they are not detectable in hospital laboratories. Three of these products, BZP (1- benzylpiperazine), mefedrone (4-methylmethcathinone) and Spice are probably the most widely used in Europe. The first two are consumed as an alternative to ecstasy and cocaine and are characterized by their producing a clinical profile of a sympathetic mimetic type; on occasion, they have serious consequences, with convulsions and even death. Spice (a mixture of herbs with synthetic cannabinoids such as JWH-018, JWH-073 and CP 47497-C8) is giving rise to profiles of dependence and schizophrenia. Although the emergent drugs have an aura of safety, there is an increasing amount of experience on their secondary effects.Downloads
References
1. ÁLVAREZ VARA C. Éxtasis: un viejo éxito inquietante. Rev Clin Esp 2010; 210: 394-396.
https://doi.org/10.1016/j.rce.2010.04.009
2. MIRO O, GALICIA M, SÁNCHEZ M, NOGUE S. Factores que determinan la reconsulta a urgencias tras una atención urgente por consumo de cocaína. Emergencias 2010; 22: 408-414.
3. SUPERVÍA A, AGUIRRE A, CLEMENTE C, IGLESIAS ML, SKAF E, ECHARTE JL. Factores que influyen en la realización de una valoración psiquiátrica en pacientes que consultan por intoxicación por cocaína. Emergencias 2010; 22: 91-95.
4. SCHIFANO F, DELUCA P, BALDACCHINO A, PELTONIEMI T, SCHERBAUM N, TORRENS M et al. Drugs on the web; the Psychonaut 2002 EU project. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 640-646.
https://doi.org/10.1016/j.pnpbp.2005.11.035
5. LEVINE DA. "Pharming": the abuse of prescription and over-the-counter drugs in teens. Curr Opin Pediatr 2007; 19: 270-274.
https://doi.org/10.1097/MOP.0b013e32814b09cf
6. Observatorio Europeo de las drogas y las Toxicomanías. Informe anual 2010: el problema de la drogodependencia en Europa. Luxemburgo: Oficina de publicaciones de la Unión Europea, 2010; 106-107. URL: http://www.emcdda.europa.eu/attachements.cfm/att_120104_ES_EMCDDA_AR2010_ES.pdf
7. NICHOLSON TC. Prevalence of use, epidemiology and toxicity of 'herbal party pills' among those presenting to the emergency department. Emerg Med Australas 2006; 18: 180-184.
https://doi.org/10.1111/j.1742-6723.2006.00826.x
8. SCHMIDT MM, SHARMA A, SCHIFANO, F, FEINMANN C. "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. Forensic Sci Int 2010; 206: 92-97.
https://doi.org/10.1016/j.forsciint.2010.06.030
9. BURILLO-PUTZE G, CLIMENT GARCÍA B, MEDINA VEGA L, TOLEDO RAVELO A. Las smart-drugs: un nuevo reto clínico en urgencias y emergencias. Emergencias 2010; 22: 477-478.
10. GALICA M, NOGUÉ S, SANJURJO E, MIRÓ O. Evolución de las consultas urgentes relacionadas con el consumo de cocaína durante el periodo 2002-2007. Emergencias 2008; 20: 385-390.
11. LEÓN-QUINTANA C, AYALA-RODRIGO A, DOMÍNGUEZ-SUÁREZ M, CASTRO-CONDE JR, BURILLO-PUTZE G. Estado confusional agudo de causa tóxica. Rev Neurol. 2006 Jun 1-15; 42: 703-734.
https://doi.org/10.33588/rn.4211.2005667
12. AUWÄRTER V, DRESEN S, WEINMANN W, MÜLLER M, PÜTZ M, FERREIRÓS N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009; 44: 832-837.
https://doi.org/10.1002/jms.1558
13. OVASKA H, VILJOEN A, PUCHNAREWICZ M, BUTTON J, RAMSEY J, HOLT DW, DARGAN PI et al. First case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicological screening. Eur J Emerg Med 2008; 15: 354-356.
https://doi.org/10.1097/MEJ.0b013e3282fc765b
14. FERNÁNDEZ EGIDO C, GARCÍA HERRERO G, ROMERO GARCÍA R, MARQUINA SANTOS AJ. Intoxicaciones agudas en las urgencias extrahospitalarias. Emergencias 2008; 20: 328-331.
15. BURILLO-PUTZE G, GARCÍA BC, GONZÁLEZ AM. Uso de nuevos cannabinoides (Spice) y su detección en Urgencias. An Pediatr (Barc) 2010; 73: 287-288.
https://doi.org/10.1016/j.anpedi.2010.07.012
16. Observatorio Europeo de las drogas y las Toxicomanías. Informe anual 2008: el problema de la drogodependencia en Europa. Luxemburgo: Oficina de publicaciones de la Unión Europea, 2008. Disponible en URL: http://www.emcdda.europa.eu/attachements.cfm/att_64227_ES_EMCDDA_AR08_es.pdfhttp://www.emcdda.europa.eu/attachements.cfm/att_120104_ES_EMCDDA_AR2010_ES.pdf
17. European Monitoring Centre for Drugs and Drug Addiction. Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances. Luxembourg: Office for Official Publications of the European Communities, 2009.
18. BYE C, MUNRO-FAURE AD, PECK AW, YOUNG PA. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 1973; 6: 163-169.
https://doi.org/10.1007/BF00558280
19. CAMPBELL H, CLINE W, EVANS M, LLOYD J, PECK AW. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 1973; 6: 170-176.
https://doi.org/10.1007/BF00558281
20. GEE P, RICHARDSON S, WOLTERSDORF W, MOORE G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zeland. N Z Med J 2005; 118 (1227): U1784.
21. BAUMANN MH, CLARK RD, BUDZYNSKI AG, PARTILLA JS, BLOUGH BE, ROTHMAN RB. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 2005; 30: 550-560.
https://doi.org/10.1038/sj.npp.1300585
22. GEE P, GILBERT M, RICHARDSON S, MOORE G, PATERSON S, GRAHAM P. Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol (Phila) 2008; 46: 802-807.
https://doi.org/10.1080/15563650802307602
23. WIKSTRÖM M, HOLMGREN P, AHLNER J. A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol 2004; 28: 67-70.
https://doi.org/10.1093/jat/28.1.67
24. CLEMENTE RODRÍGUEZ C, AGUIRRE TEJEDO A, ECHARTE JL, PUENTE PALACIUOS I, IGLESIAS EPINE ML, SUPERVÍA CAPARRÓS A. Diferencias entre hombres y mujeres en las características de las intoxicaciones. Emergencias 2010; 22: 435-440.
25. ELLIOTT S, SMITH C. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol 2008; 32: 172-177.
https://doi.org/10.1093/jat/32.2.172
26. Council Decision 2008/206/JHA of 3 March 2008 on defining 1-benzylpiperazine (BZP) as a new psychoactive substance which is to be made subject to control measures and criminal provisions. Official Journal of the European Union. 7 de marzo 2008. L 63/45.
27. Ministerio de Sanidad y Política Social. Orden SAS/1916/2009, de 8 de julio, por la que se incluye la sustancia 1- benzilpiperazina (BZP) en el anexo I del Real Decreto 2829/1977, de 6 de octubre, por el que se regula la fabricación, distribución, prescripción y dispensación de sustancias y preparados psicotrópicos. Boletín Oficial del Estado Núm. 172 Viernes 17 de julio de 2009.
28. NOGUE S, RAMOS A, PORTILLO M, BOHILS M. Adecuación de un sistema de triaje y del circuito asistencial en urgencias al paciente intoxicado. Emergencias 2010; 22: 338-344.
29. WOOD DM, DARGAN PI, BUTTON J, HOLT DW, OVASKA H, RAMSEY J et al. Collapse, reported seizure--and an unexpected pill. Lancet 2007; 369: 1490.
https://doi.org/10.1016/S0140-6736(07)60674-6
30. JAMES D, ADAMS RD, SPEARS R, COOPER G, LUPTON DJ, THOMPSON JP et al; on behalf of the National Poisons Information Service. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 2010 (en prensa).
https://doi.org/10.1136/emj.2010.096636
31. DICK D, TORRANCE C. Mix Mag drugs survey. Mix Mag 2010; 225: 44-53.
https://doi.org/10.1109/MAP.2011.6028469
32. ODENWALD M, NEUNER F, SCHAUER M, ELBERT T, CATANI C, LINGENFELDER B et al. Khat use as risk factor for psychotic disorders: a cross-sectional and case-control study in Somalia. BMC Med 2005; 3: 5.
https://doi.org/10.1186/1741-7015-3-5
33. AL-MOTARREB A, BRIANCON S, AL-JABER N, AL-ADHI B, AL-JAILANI F, SALEK MS et al. Khat chewing is a risk factor for acute myocardial infarction: a case-control. study. Br J Clin Pharmacol 2005; 59: 574-581.
https://doi.org/10.1111/j.1365-2125.2005.02358.x
34. GRIFFITHS P, LÓPEZ D, SEDEFOV R, GALLEGOS A, HUGHES B, NOOR A, et al. Khat use and monitoring drug use in Europe: the current situation and issues for the future. J Ethnopharmacol 2010; 132: 578-583.
https://doi.org/10.1016/j.jep.2010.04.046
35. GRIFFITHS P, LOPEZ D, SEDEFOV R, GALLEGOS A, HUGHES B, NOOR A, et al. Khat use and monitoring drug use in Europe: the current situation and sigues for the future. J Ethnopharmacol 2010; 132: 578-583.
https://doi.org/10.1016/j.jep.2010.04.046
36. BURILLO-PUTZE G, BALANZÓ X. Desmontando clichés sobre inmigración y salud. An Sist Sanit Navar 2010; 33:127-131.
https://doi.org/10.4321/S1137-66272010000300001
37. FUERTES MC, ELIZALDE L , DE ANDRÉS MR, GARCÍA CASTELLANO P , URMENETA S, URIBE JM et al. Atención al paciente inmigrante: realidad y percepción de los profesionales de 6 zonas de Atención Primaria de Navarra. An Sist Sanit Navar 2010; 33: 57-68.
https://doi.org/10.4321/S1137-66272010000300006
38. FUERTES C, TRUJILLO E, PINILLOS M, BALANZÓ X, MIRÓ O, BURILLO-PUTZE G. Atención a la diversidad en Urgencias. An Sist Sanit Navar 2010; 33 (Suppl 1): 149-61.
https://doi.org/10.4321/S1137-66272010000200016
39. ARCHER RP. Fluoromethcathinone, a new substance of abuse. Forensic Sci Int 2009; 185: 10-20.
https://doi.org/10.1016/j.forsciint.2008.11.013
40. EMERSON TS, CISEK JE. Methcathinone: a Russian designer amphetamine infiltrates the rural midwest. Ann Emerg Med 1993; 22): 1897-1903.
https://doi.org/10.1016/S0196-0644(05)80419-6
41. STEPENS A, LOGINA I, LIGUTS V, ALDINS P, EKSTEINA I, PLATKĀJIS A et al. A Parkinsonian syndrome in methcathinone users and the role of manganese. N Engl J Med 2008; 358: 1009-1017.
https://doi.org/10.1056/NEJMoa072488
42. DARGAN P, WOOD D. La valoración psiquiátrica en los pacientes con intoxicación por cocaína. Emergencias 2010; 22: 83-84.
43. WOOD DM, DAVIES S, GREENE SL, BUTTON J, HOLT DW, RAMSEY J et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila) 2010; 48: 924-927.
https://doi.org/10.3109/15563650.2010.531021
44. TORRANCE H, COOPER G. The detection of mephedrone (4-methylmethcatinone) in 4 fatalities in Scotland. Forensic Sci Int 2010; 202: e62-63.
https://doi.org/10.1016/j.forsciint.2010.07.014
45. European Monitoring Centre for Drugs and Drug Addiction. Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone). Disponible en URL: http://www.emcdda.europa.eu/attachements.cfm/att_116485_EN_Risk%20Assessment%20Report%20on%20mephedrone.pdf
46. Council Decision of 2 December 2010 on submitting 4-methylmethcathinone (mephedrone) to control measures. Official Journal of the European Union. Disponible en URL: http://www.emcdda.europa.eu/attachements.cfm/att_121058_EN_Council_Decision_2010_759_EU_2_December_2010.pdf
47. Ministerio de Sanidad, Política Social e Igualdad. Orden SPI/201/2011, de 3 de febrero, por la que se incluye la sustancia 4-metilmetcatinona (Mefedrona) en el Anexo I del Real Decreto 2829/1977, de 6 de octubre, por el que se regula la fabricación, distribución, prescripción y dispensación de sustancias y preparados psicotrópicos. Boletín Oficial del Estado de 9 de febrero de 2011.
48. WINSTOCK A, MITCHESON L, MARSDEN J. Mephedrone: still available and twice the price. Lancet 2010; 376: 1537.
https://doi.org/10.1016/S0140-6736(10)62021-1
49. European Monitoring Centre for Drugs and Drug Addiction. EMCDDA 2009 Thematic paper - Understanding the 'Spice' phenomenon. Luxembourg: Office for Official Publications of the European Communities, 2009. Disponible en URL: http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spice%20Thematic%20paper%20-%20final%20version.pdf (EMCCDA, Undrestanding the Spice phenomenon)
50. MUSTATA C, TORRENS M, PARDO R, PÉREZ C; Psychonaut Web Mapping Group, Farré M. Spice drugs: los cannabinoides como nuevas drogas de diseño. Adicciones. 2009; 21: 181-186.
https://doi.org/10.20882/adicciones.227
51. LINDIGKEIT R, BOEHME A, EISERLOH I, LUEBBECKE M, WIGGERMANN M, ERNST L, BEUERLE T. Spice: a never ending story? Forensic Sci Int 2009; 191: 58-63.
https://doi.org/10.1016/j.forsciint.2009.06.008
52. MÜLLER H, SPERLING W, KÖHRMANN M, HUTTNER HB, KORNHUBER J, MALER JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010; 118: 309-310.
https://doi.org/10.1016/j.schres.2009.12.001
53. ZIMMERMANN US, WINKELMANN PR, PILHATSCH M, NEES JA, SPANAGEL R, SCHULZ K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int 2009; 106: 464-467.
https://doi.org/10.3238/arztebl.2009.0464
54. NOGUE S. Toxicólogo y urgenciólogo: una nueva variante del cangrejo ermitaño. Emergencias 2009; 21: 62-64.
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2011 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
